Casdin Capital LLC Invests $8.25 Million in Taysha Gene Therapies, Inc. $TSHA

Casdin Capital LLC acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) in the fourth quarter, Holdings Channel reports. The fund acquired 1,500,000 shares of the company’s stock, valued at approximately $8,250,000. Taysha Gene Therapies comprises 0.5% of Casdin Capital LLC’s investment portfolio, making the stock its 28th biggest position.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TSHA. Marex Group plc bought a new position in shares of Taysha Gene Therapies during the 2nd quarter worth about $29,000. E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 2nd quarter worth about $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Taysha Gene Therapies during the 3rd quarter worth about $40,000. Tower Research Capital LLC TRC lifted its holdings in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after acquiring an additional 10,742 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Taysha Gene Therapies by 51.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock worth $43,000 after acquiring an additional 6,350 shares during the period. 77.70% of the stock is owned by institutional investors.

Get Taysha Gene Therapies alerts:

Insider Activity

In related news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the transaction, the insider owned 1,136,410 shares of the company’s stock, valued at $5,068,388.60. This trade represents a 14.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Chardan Capital restated a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Canaccord Genuity Group boosted their price target on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, April 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $11.64.

Get Our Latest Stock Analysis on TSHA

Taysha Gene Therapies Stock Up 5.8%

Shares of NASDAQ TSHA opened at $6.19 on Thursday. The firm has a market capitalization of $1.78 billion, a PE ratio of -16.29 and a beta of 1.19. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 1 year low of $2.25 and a 1 year high of $7.30. The firm’s 50-day moving average is $5.86 and its 200-day moving average is $5.20.

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Equities analysts expect that Taysha Gene Therapies, Inc. will post -0.5 EPS for the current year.

About Taysha Gene Therapies

(Free Report)

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

Read More

• Five stocks we like better than Taysha Gene Therapies
• Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
• CoreWeave Insider Sales Look Big, But Should Investors Worry?
• Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
• Meta and Cloud Computing: Real Potential, or a Shot in the Dark?

Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report).

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.